Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients

导出原文传递

翻译打印收藏纠错

作者： Lin, MaoFang ^[1] ; Hou, Jian ^[2] ; Chen, WenMing ^[3] ; Huang, XiaoJun ^[4] ; Liu, ZhuoGang ^[5] ; Zhou, YuHong ^[6] ; Li, Yan ^[7] ; Zhao, Taiyun ^[8] ; Wang, LinNa ^[9] ; Wu, Kwang-Wei ; Shen, ZhiXiang

作者单位： Zhejiang Prov Tradit Chinese Med Hosp, Dept Hematol, Shenyang, Liaoning, Peoples R China ^[1] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China ^[2] Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China ^[3] Xian Janssen Pharmaceut Co, Beijing, Peoples R China ^[4] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hematol, Hangzhou, Zhejiang, Peoples R China ^[5] China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China ^[6] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China ^[7] China Med Univ, Affiliated Hosp 1, Shenyang, Liaoning, Peoples R China ^[8] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China ^[9]

关键词 Bortezomib Chinese Multiple myeloma Observational study Refractory Relapsed Response

发布时间 2015-03-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交